Cellectar Biosciences宣布高达1.4亿美元的融资交易;股价飙升

2026-05-05 21:02

Cellectar Biosciences (CLRB) entered agreements with institutional investors and management to raise capital.
The deal includes ~$35M upfront funding plus up to ~$105M tied to milestone-based securities.
Financing is structured as a registered direct offering of common stock and a concurrent private placement.
Securities issued include common stock, pre-funded warrants, and milestone-based warrants.
Proceeds are expected to support development of its targeted oncology therapies pipeline.
CLRB shares up 51.6% premarket.

More on Cellectar Biosciences